FluoroPharma Medical, Inc. (FPMI)

[MissionIR]

FluoroPharma Medical Due Diligence Summary

Company Website
http://www.fluoropharma.com

FluoroPharma IR Kit
http://fpmi.missionir.com/ir

FluoroPharma Fact Sheet
http://fpmi.missionir.com/factsheet

FluoroPharma Presentation
http://fpmi.missionir.com/presentation

Stock Info
http://finance.yahoo.com/q?s=FPMI.OB
http://www.otcmarkets.com/stock/FPMI/quote

Abbreviated Company Profile

FluoroPharma Medical, Inc. is a biopharmaceutical company focused on discovering and developing patented Positron Emission Tomography (PET) imaging products to improve patient management by evaluating cardiac disease at the cellular and molecular levels. The company is currently advancing two products in clinical trials to fulfill critical unmet medical needs. The agents will provide clinicians important tools for detecting and assessing pathology before critical manifestations of disease.

Molecular imaging fulfills numerous unmet needs in diagnosis by enabling visualization, characterization and measurement of biological processes at the molecular and cellular level. Unlike traditional imaging modalities – MRI, CT, and Ultrasound – that reveal the anatomical abnormalities and cause for disease, PET provides insight into physiology and can detect disease before anatomical manifestation is identified. According to GAI, the market for molecular imaging agents currently exceeds $1.7 billion annually and promises rapid growth for the foreseeable future.

Key Investment Highlights

• Clinical Trials Confirmed Technologies are Safe and are Now
• Establishing their Efficacy
• Intellectual Property in Place to Protect Proprietary Innovations Around the World
• Cash On Hand to Accelerate Business Strategy
• Technology Targets Multiple, Multimillion Dollar Healthcare Markets with Strong / Unmet Medical Needs

Company News
http://www.fluoropharma.com/media-center/company-news

Share Structure

Shares Outstanding 21,094,024 a/o September 30, 2011
Authorized Shares 200,000,000 a/o September 30, 2011

Management

David R. Elmaleh, PhD
Chairman, Director and Chief Scientific Advisor

Dr. Elmaleh, the scientific founder of FluoroPharma Inc., is an Associate Professor at Harvard Medical School and the Director of Contrast Media Chemistry at the Massachusetts General Hospital. He is an inventor of three drugs that are in use in man or in late stage clinical trials including: The radiopharmaceutical preparation of (2FDG) which has been used in over a million PET imaging procedures, Beta-methyl modified fatty acid (BMIPP) a commercially successful cardiac SPECT agent, and Altropane which has completed Phase III clinical trials. His recent work has included extensive research on imaging compounds to improve the speed and effectiveness of cardiovascular disease diagnosis which constitutes the technology licensed from MGH to FluoroPharma. He is a co-author on over 120 publications and an inventor of over 40 issued and pending patents in a range of disciplines, including molecular imaging and pharmaceuticals. Dr. Elmaleh is a recipient of numerous NIH and DOE awards, and has participated as a reviewer for the National Institute of Health (NIH). He is the Scientific Founder of Biostream (changed name to Molecular Insight Pharmaceuticals) and several other start-ups. He holds a BSc in Physics and Chemistry, and an MS and PhD in Chemistry from the Hebrew University of Jerusalem.

Thijs Spoor
Director, CEO & President

Mr. Spoor previously held the title of CFO for Sunstone BioSciences. Mr. Spoor holds a Nuclear Pharmacy degree from the University of Toronto as well as an M.B.A. from Columbia University with concentrations in finance and accounting. Mr. Spoor has been a guest lecturer at Columbia Business School, Kings College in London and the University of Newcastle in Australia and has presented at medical grand rounds and psychiatric grand rounds at various hospitals on the role of brain imaging.

Prior to joining Sunstone BioSciences, he worked as a consultant at Oliver Wyman focusing on helping pharmaceutical and medical device companies evaluate their global revenue potential given the complex interplay of regulatory approvals, the reimbursement environment, as well as the impact of physician preference within constantly evolving standards of care. He further specialized on the implications of healthcare reform on new product approval and health insurance reform.

Mr. Spoor has also been an equity research analyst at J.P. Morgan and Credit Suisse covering the Biotechnology and Medical Device industries. Mr. Spoor worked in the pharmaceutical industry spending 10 years with Amersham / GE Healthcare where he worked in 7 countries in a variety of roles including setting up GMP facilities meeting ISO 9001 standards, accountability for the entire nuclear cardiology portfolio and most recently as the Director of New Product Opportunities leading the PET strategic plan.

Boyan Goumnerov, MD
COO & Vice President Clinical Trials

Prior to his appointment with FluoroPharma Dr. Goumnerov has held executive positions in the healthcare and biomedical research fields most recent of which are President of VasoStent, Inc. and managing director of CardioVas Inc.- start-up medical device companies targeting the field of intravascular cardiac imaging and therapy. His academic background includes research within the departments of Surgery and Molecular Biology at the Massachusetts General Hospital (MGH) and The Shriners Burn Hospital for Children, Boston, where he held academic appointments with Harvard Medical School. Dr. Goumnerov also did extensive work within the Department of Pathology/Neuropathology at Children's Hospital Boston, in developing image analysis protocols for evaluation of neuromuscular diseases before moving to MGH. He is co-author of numerous scientific publications. Dr. Goumnerov obtained his M.D. from the Medical University of Sofia, Bulgaria, and worked as a clinician prior to relocating to the US.

Auditors

MartinelliMick PLLC
Rock Pointe Tower
316 W Boone, Ste 777
Spokane, WA 99201
T: [phone]

Transfer Agent

Holladay Stock Transfer
2939 N. 67th Place
Scottsdale, AZ 85251
T: [phone]

Company Contact

FluoroPharma Medical, Inc.
Boston, Massachusetts
http://www.fluoropharma.com
T: [phone]
E: [e-mail]

IR Contact

Mission Investor Relations
Atlanta, Georgia
http://www.missionir.com
T: [phone]
E: [e-mail]